Previously, we observed that MYBMIM blocks the binding of MYB to CBP/P300 in AML cells, requiring relatively high 20 μM concentrations for 3 hr to achieve this effect (Ramaswamy et al., 2018). Here, EP300 is linked to acute myeloid leukemia.